CIPRO A

Ciprofloxacin HCl

Antiinfective » Quinolones

 
 
 
 
 


Indication

General: Urinary tract infections, Skin and soft tissue infections, Typhoid fever, Gonorrhea and other sexually transmitted diseases, Bacterial gastrointestinal infections, Bone and joint infections, Osteomyelitis, Infectious diarrhea, Surgical prophylaxis, Gynecological infection, Other infections.

Eye : For the treatment of corneal ulcers and conjunctivitis caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Pseudomonous aeruginosa etc.

Ear : Otitis externa, acute otitis media, chronic suppurative otitis media. Prophylaxis in otic surgeries such as mastoid surgery.


Dosage and Administration

Infection

Type of Severity

Unit Dose

Frequency

Usual Durations

Urinary tract

Acute Uncomplicated

100 mg or

 250 mg

b.i.d

3 Days

Mild/Moderate

250 mg

b.i.d

7-14 days

Severe/Complicated

500 mg

b.i.d

7-14 days

Chronic Bacterial Prostatitis

Mild/Moderate

500 mg

b.i.d

28 days

Lower Respiratory Tract

Mild/Moderate

500 mg

b.i.d

7-14 days

Severe/Complicated

750 mg

b.i.d

7-14 days

Acute Sinusitis

Mild/Moderate

500 mg

b.i.d

10 days

Skin & Skin Structure

Mild/Moderate

500 mg

b.i.d

7-14 days

Severe/Complicated

750 mg

b.i.d

7-14 days

Bone and Joint

Mild/Moderate

500 mg

b.i.d

³ 4-6 Weeks

Severe/Complicated

750 mg

b.i.d

³ 4-6 Weeks

Intra-Abdominal

Complicated

500 mg

b.i.d

7-14 days

Infectious Diarrhea

Mild/Moderate/Severe

500 mg

b.i.d

5-7 days

Typhoid Fever

Mild/Moderate

500 mg

b.i.d

10 days

Urethral and Cervical Gonococcal Infections

Uncomplicated

 250 mg

Single dose

Single dose

Inhalational anthrax (Post-exposure)

Adult

500 mg

b.i.d

60 days

Pediatric

15 mg/kg per dose, not to exceed 500 mg per dose

b.i.d

60 days

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms have disappeared, except for inhalational anthrax (Post -exposure).

Patients whose therapy is started with Ciprofloxacin I.V. may be switched to Ciprofloxacin Tablets or Suspension when clinically indicated at the discretion of the physician.

Pediatric patients & adolescents (1- 17 years of age): Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli.

Pediatric Dosage Guideline

Infection

Route of Administration

Dose (mg/kg)

Frequency

Total Duration

Complicated Urinary Tract or Pyelonephritis (Pyelonephritis (Patients from 1 to 17 years of age)

Oral

10 mg/kg to 20 mg/kg (maximum 750 mg per dose; not to be exceeded even in patients weighing >51 kg)

b.i.d

10-21 days

Inhalational Anthrax (Post-Exposure

Oral

15 mg/kg (maximum 500 mg per dose)

b.i.d

60 days

 

 

 

 

 

 

 

 

 

 

 

 

The dosage of Cipro-A IV Infusion is determined by the severity and type of infection, the sensitivity of the causative organisms and the age, weight, and renal function of the patient. The usual intravenous dose is 100 mg to 400 mg twice daily.

Indications

Dosage

Infusion Rate

Duration

Upper and Lower UTI

100 mg (50 ml) b.d.

Should be administ-ered by slow intraven-ous infusion over periods of 30-60 minutes

The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings. The usual duration of therapy for acute infections is  7-14 days.

Upper and lower respiratory tract infections (depending on severity and sensitivity of causative organism)

200 mg–400 mg b.d.

Cystic fibrosis patients with pseudomonal lower RTI

400 mg b.d.

Other infections

200 mg – 400 mg b.d.

Gonorrhoea

100 mg single dose

Inhalation Anthrax

400 mg b.d.

Impaired renal function


Dosage adjustments are not usually required, except in patients with severe renal impairment (serum creatinine >265 micromole/l or creatinine clearance <20 ml/minute). If adjustment is necessary, this may be achieved by reducing the total daily dose by half, although monitoring of drug serum levels provides the most reliable basis for dose adjustment.

Children : Child not recommended but where benefit outweighs risk, by intravenous infusion, 8-16 mg/kg body weight daily in 2 divided doses.

Or as directed by the physician.


Eye : Corneal ulcer - 2 drops to be instilled into the affected eye every 15 minutes for the first six hours and then every 30 minutes for the rest of the day when the patient is awake. On the second day 2 drops every hour; from the third day every 4 hours. Bacterial conjunctivitis - 1 to 2 drops to be instilled to the affected eye every two hours for 2 days, and every 4 hours for the next five days.

Ear: For all infections 2 - 3 drops every 2 - 3 hours initially while reducing the frequency of the instillation with control of infection.


Composition

Cipro-A 250 mg Tablet : Each film-coated tablet contains Ciprofloxacin (as hydrochloride) USP 250 mg.

Cipro-A 500 mg Tablet : Each film-coated  tablet contains Ciprofloxacin (as hydrochloride) USP 500 mg.

Cipro-A 750 mg Tablet: Each film-coated tablet contains Ciprofloxacin (as hydrochloride) USP 750 mg.

Cipro-A pellets for Suspension : After reconstitution each 5 ml contains Ciprofloxacin (as hydrochloride) USP 250 mg.

Cipro-A IV Infusion : Each 100 ml contains Ciprofloxacin USP 200 mg (as Ciprofloxacin Lactate INN).

Cipro-A Eye & Ear Drops : Each ml contains Ciprofloxacin USP 3 mg

 
 

Other Antiinfective Products